New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs
Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has contributed a very effective approach. However, many patients do not achieve, at the maximal tolerated dose, the recommended goals for low-density lipoprotein-cholesterol (LDL-C), non-high-density lipopro...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
Oxford University Press
2013
|
| Online Access: | http://hdl.handle.net/20.500.11937/55365 |
| _version_ | 1848759602534940672 |
|---|---|
| author | Norata, Giuseppe Ballantyne, C. Catapano, A. |
| author_facet | Norata, Giuseppe Ballantyne, C. Catapano, A. |
| author_sort | Norata, Giuseppe |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has contributed a very effective approach. However, many patients do not achieve, at the maximal tolerated dose, the recommended goals for low-density lipoprotein-cholesterol (LDL-C), non-high-density lipoprotein-cholesterol, and apolipoprotein B (apoB). Available agents combined with statins can provide additional LDL-C reduction, and agents in development will increase therapeutic options impacting also other atherogenic lipoprotein classes. In fact, genetic insights into mechanisms underlying regulation of LDL-C levels has expanded potential targets of drug therapy and led to the development of novel agents. Among them are modulators of apoB containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 inhibitors. Alternative targets such as lipoprotein(a) also require attention; however, until we have a better understanding of these issues, further LDL-C lowering in high and very high-risk patients will represent the most sound clinical approach. © 2013 Author(s). |
| first_indexed | 2025-11-14T10:02:30Z |
| format | Journal Article |
| id | curtin-20.500.11937-55365 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:02:30Z |
| publishDate | 2013 |
| publisher | Oxford University Press |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-553652023-02-22T06:24:19Z New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs Norata, Giuseppe Ballantyne, C. Catapano, A. Dyslipidaemias play a key role in determining cardiovascular risk; the discovery of statins has contributed a very effective approach. However, many patients do not achieve, at the maximal tolerated dose, the recommended goals for low-density lipoprotein-cholesterol (LDL-C), non-high-density lipoprotein-cholesterol, and apolipoprotein B (apoB). Available agents combined with statins can provide additional LDL-C reduction, and agents in development will increase therapeutic options impacting also other atherogenic lipoprotein classes. In fact, genetic insights into mechanisms underlying regulation of LDL-C levels has expanded potential targets of drug therapy and led to the development of novel agents. Among them are modulators of apoB containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 inhibitors. Alternative targets such as lipoprotein(a) also require attention; however, until we have a better understanding of these issues, further LDL-C lowering in high and very high-risk patients will represent the most sound clinical approach. © 2013 Author(s). 2013 Journal Article http://hdl.handle.net/20.500.11937/55365 10.1093/eurheartj/eht088 Oxford University Press unknown |
| spellingShingle | Norata, Giuseppe Ballantyne, C. Catapano, A. New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs |
| title | New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs |
| title_full | New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs |
| title_fullStr | New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs |
| title_full_unstemmed | New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs |
| title_short | New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs |
| title_sort | new therapeutic principles in dyslipidaemia: focus on ldl and lp(a) lowering drugs |
| url | http://hdl.handle.net/20.500.11937/55365 |